Cadila Recalls Antidepressant from U.S. Market

Share This:

Cadila Healthcare, an Indian pharmaceuticals manufacturer, reportedly issued a recall of certain lots of its generic antidepressant drug, venlafaxine hydrochloride, from the U.S. market.

The Business Standard reports that the recall was issued in March over complaints of a large number of broken and chipped tablets in certain lots. The recalled drugs were produced at the Ahmedabad plant in India and distributed in the U.S. by Zydus Pharmaceuticals, a unit of Cadila.

Cadila’s venlafaxine hydrochloride tablets are a generic version of Pfizer’s Effexor. The recall falls under the U.S. Food and Drug Administration’s Class ll status, according to the Standard. This means the drug may cause temporary or medically reversible adverse side effects.

Cadila is the latest Indian drug maker to recall product from the U.S. Ranbaxy, Glenmark, and Dr. Reddy’s Lab’s have all issued drug recalls following complaints in the U.S. market, reports the Standard.

If you or a loved one has been harmed by a dangerous drug, contact Sokolove Law today for a free legal consultation and to find out if a dangerous drug lawyer may be able to help you.